FLAG Therapeutics
Business Services · North Carolina, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
9168 Wooden Rd, Raleigh, North Carolina,...Phone Number
(919) 294-6472Website
www.flagtherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About FLAG Therapeutics
FLAG Therapeutics is a clinical stage company dedicated to developing small molecule therapeutics for challenging cancers. Their lead candidate, FLAG-003, targets Diffuse Intrinsic Pontine Glioma (DIPG) and glioblastoma multiform (GBM), with plans to enter Phase 1 clinical development in early 2026. The company focuses on innovative solutions for difficult-to-treat cancers, aiming to improve outcomes for pediatric patients. FLAG Therapeutics collaborates with various investors and foundations to support its mission.Explore more
FLAG Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is FLAG Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if FLAG Therapeutics is spiking on competitors!
Check if FLAG Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on FLAG Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when FLAG Therapeutics launches new products
Funding: Get notified immidiatlly once FLAG Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
FLAG Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at FLAG Therapeutics
Click to see if FLAG Therapeutics had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined FLAG Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to FLAG Therapeutics
Compare insights from companies similar to FLAG Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
FLAG Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
FLAG Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about FLAG Therapeutics.
FLAG Therapeutics financials insights
Gather financial insights about FLAG Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Private Equity
$500K
2021
Debt
$73K
FLAG Therapeutics Tech Stack
A closer look at the technologies used by FLAG Therapeutics
FLAG Therapeutics News & Media
FLAG Therapeutics Receives Rare Pediatric Disease (RPD) Designation for FLAG-003 for the Treatment of Children with Diffuse Intrinsic Pontine Glioma (DIPG)
RALEIGH, N.C., Jan. 31, 2023 (GLOBE NEWSWIRE) -- FLAG Therapeutics, Inc., announced today that FLAG-003, an investigational small molecule therapy for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG), a rare, highly aggressive and difficult to treat brain tumor found in children, has been granted Rare Pediatric Disease (RPD) designation from the U.S. Food and Drug Administration (FDA). FLAG-003, the company’s lead program for the treatment of all gliomas, is engineered to cross the blood
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding FLAG Therapeutics
Sign Up For FreeTo access detailed company insights
FLAG Therapeutics is a clinical stage company dedicated to developing small molecule therapeutics for challenging cancers. Their lead candidate, FLAG-003, targets Diffuse Intrinsic Pontine Glioma (DIPG) and glioblastoma multiform (GBM), with plans to enter Phase 1 clinical development in early 2026. The company focuses on innovative solutions for d... Read More
